Analysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 233-239

  Guo, Hongyan ^a   Liu, Chang ^a   Liu, Bin ^a   Wood, Charles ^b   Kong, Xiaohong ^a  

^a NANKAI UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA   (United States)

Author keywords

MTCT HIV 1 Subtype C Primary resistance Maraviroc Vicriviroc

Indexed keywords

MARAVIROC; VICRIVIROC;

ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MOTHER CHILD RELATION; PREVALENCE; PRIORITY JOURNAL; PROVIRUS; VIRUS ENTRY; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ZAMBIA;

EID: 84881556582     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.05.022     Document Type: Article

References (29)

1. Alcantara K.C., Lins J.B., Albuquerque M., Aires L.M., Cardoso L.P., Minuzzi A.L., et al. HIV-1 mother-to-child transmission and drug resistance among Brazilian pregnant women with high access to diagnosis and prophylactic measures. J Clin Virol 2012, 54:15-20.
2. Steain M.C., Wang B., Saksena N.K. Analysis of HIV-1 sequences vertically transmitted to infants in Kisumu, Kenya. J Clin Virol 2006, 36:298-302.
3. Luzuriaga K. Mother-to-child transmission of HIV: a global perspective. Curr Infect Dis Rep 2007, 9:511-517.
4. Ahmad N. The vertical transmission of human immunodeficiency virus type 1: molecular and biological properties of the virus. Crit Rev Clin Lab Sci 2005, 42:1-34.
5. World WOH: antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach. 2006 version 2006, Available: http://www.whoint/hiv/pub/guidelines/pmtctguidelines3pdf.
6. World WOH: antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. 2010 version 2010, Available: http://whqlibdocwhoint/publications/2010/9789241599818_engpdf.
7. Ciaranello A.L., Perez F., Maruva M., Chu J., Engelsmann B., Keatinge J., et al. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. PLoS ONE 2011, 6:e20224.
8. Aghokeng A.F., Kouanfack C., Laurent C., Ebong E., Atem-Tambe A., Butel C., et al. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 2011, 25:2183-2188.
9. Arrive E., Newell M.L., Ekouevi D.K., Chaix M.L., Thiebaut R., Masquelier B., et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007, 36:1009-1021.
10. Hauser A., Sewangi J., Mbezi P., Dugange F., Lau I., Ziske J., et al. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. PLoS ONE 2011, 7:e32055.
11. Hamers R.L., Wallis C.L., Kityo C., Siwale M., Mandaliya K., Conradie F., et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011, 11:750-759.
12. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U.S.A. 2000, 97:5639-5644.
13. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003, 77:5201-5208.
14. Lobritz M.A., Ratcliff A.N., Arts E.J. HIV-1 entry, inhibitors, and resistance. Viruses 2010, 2:1069-1105.
15. Berro R., Klasse P.J., Jakobsen M.R., Gorry P.R., Moore J.P., Sanders R.W. V3 determinants of HIV-1 escape from the CCR5 inhibitors maraviroc and vicriviroc. Virology 2012, 427:158-165.
16. Rachlis A., Harris M., Lalonde R., Shafran S.D., Tremblay C., Wainberg M.A., et al. Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. Can J Infect Dis Med Microbiol 2010, 21:159-172.
17. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
18. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007, 81:2359-2371.
19. Tsibris A.M., Sagar M., Gulick R.M., Su Z., Hughes M., Greaves W., et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008, 82:8210-8214.
20. Ogert R.A., Wojcik L., Buontempo C., Ba L., Buontempo P., Ralston R., et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373:387-399.
21. Araujo L.A., Junqueira D.M., de Medeiros R.M., Matte M.C., Almeida S.E. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC. J Clin Virol 2012, 54:6-10.
22. Gonzalez S., Gondwe C., Tully D.C., Minhas V., Shea D., Kankasa C., et al. Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia. AIDS Res Hum Retroviruses 2010, 26:795-803.
23. Hoffmann F.G., He X., West J.T., Lemey P., Kankasa C., Wood C. Genetic variation in mother-child acute seroconverter pairs from Zambia. AIDS 2008, 22:817-824.
24. Zhang H., Hoffmann F., He J., He X., Kankasa C., West J.T., et al. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006, 3:73.
25. Mantina H., Kankasa C., Klaskala W., Brayfield B., Campbell J., Du Q., et al. Vertical transmission of Kaposi's sarcoma-associated herpesvirus. Int J Cancer 2001, 94:749-752.
26. Zhang H., Tully D.C., Hoffmann F.G., He J., Kankasa C., Wood C. Restricted genetic diversity of HIV-1 subtype C envelope glycoprotein from perinatally infected Zambian infants. PLoS ONE 2010, 5:e9294.
27. Shang L., Yue L., Hunter E. Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. J Virol 2008, 82:5417-5428.
28. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303:2019-2022.
29. Kong X., West J.T., Zhang H., Shea D.M., M'Soka T.J., Wood C. The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses. J Virol 2008, 82:11609-11618.